Lian Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lian Li has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Yuan Huang
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
15 shared publications Chendong Liu
Key Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province West China School of Pharmacy Department of Pharmacy West China Hospital Sichuan University Chengdu 610041 China
8 shared publicationsJunlin Li
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University, Chengdu, China
7 shared publicationsPing Zhang
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University, Chengdu, China
7 shared publicationsMinglu Zhou
Key Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province West China School of Pharmacy Department of Pharmacy West China Hospital Sichuan University Chengdu 610041 China
6 shared publicationsLiqiang Chen
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
5 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (11) , 1376
Delivery Strategies Targeting Senescent Cells: From Precise Elimination to Functional Remodeling
The accumulation of senescent cells in tissues serves as a fundamental driver of aging and age-related pathologies, including chronic inflammation, tissue dysfunction, and organ degeneration. Conventional anti-aging interventions often suffer from limited specificity and off-target toxicity. Currently, developing therapeutic strategies capable of precisely targeting senescent cells is urgent. This review focuses on recent advances in delivery strategies designed to achieve either the selective elimination or functional modulation of senescent cells, with the goal of transitioning from broad-spectrum interventions to precision senotherapy. We systematically discuss the latest developments in senescence-targeting delivery platforms. To realize in vivo senescent-cell clearance, nanocarrier-based systems which are responsive to the senescent microenvironment and immune cell-based approaches are engineered. In parallel, we also reviewed emerging strategies for functional remodeling. Advanced delivery vehicles including lipid nanoparticles, extracellular vesicles, and engineered cell therapies are used to realize metabolic reprogramming and epigenetic modulation. The critical mechanisms of delivery systems in overcoming diverse barriers to improve specificity, bioavailability, and safety are highlighted. In this review, we aim to provide a preliminary framework that could serve as a useful reference for guiding the clinical translation of emerging senotherapies.
- 27 October 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (11) , 1376
Open AccessDelivery Strategies Targeting Senescent Cells: From Precise Elimination to Functional Remodeling
The accumulation of senescent cells in tissues serves as a fundamental driver of aging and age-related pathologies, including chronic inflammation, tissue dysfunction, and organ degeneration. Conventional anti-aging interventions often suffer from limited specificity and off-target toxicity. Currently, developing therapeutic strategies capable of precisely targeting senescent cells is urgent. This review focuses on recent advances in delivery strategies designed to achieve either the selective elimination or functional modulation of senescent cells, with the goal of transitioning from broad-spectrum interventions to precision senotherapy. We systematically discuss the latest developments in senescence-targeting delivery platforms. To realize in vivo senescent-cell clearance, nanocarrier-based systems which are responsive to the senescent microenvironment and immune cell-based approaches are engineered. In parallel, we also reviewed emerging strategies for functional remodeling. Advanced delivery vehicles including lipid nanoparticles, extracellular vesicles, and engineered cell therapies are used to realize metabolic reprogramming and epigenetic modulation. The critical mechanisms of delivery systems in overcoming diverse barriers to improve specificity, bioavailability, and safety are highlighted. In this review, we aim to provide a preliminary framework that could serve as a useful reference for guiding the clinical translation of emerging senotherapies.
- Open Access
- 9 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (41)
Senescent tumor cell membrane–based “time engine” nanosystem amplifies endoplasmic reticulum targeting for metastasis blockade
As an important component of biomimetic drug delivery systems, cell membrane–coated nanoparticles are widely used for subcellular delivery. However, the influence of cell membranes at different life cycles on subcellular delivery remains unexplored. Our previous study demonstrated that senescent tumor cell membrane–coated nanoparticles (SNP) displayed superior endoplasmic reticulum (ER) targeting efficiency in tumor cells. After inducing tumor cells into senescence, SNP showed greater accumulation in ER. Herein, we design a “time engine” nanosystem for amplified ER targeting: Firstly, ribociclib is encapsulated into SNP (R@SNP) to induce tumor cell senescence; then, SNP loaded with brefeldin A (B@SNP) is used to trigger ER stress. By sequential therapy, R@SNP disrupts the cytoskeleton of 4T1 tumor cells to eliminate ER-targeting barriers and remodels the tumor immune microenvironment; B@SNP boosts ER-targeting efficiency and triggers intense ER stress. Collectively, such time engine nanosystem achieves excellent ER accumulation and antimetastatic efficacy in 4T1 tumor–bearing mice, providing an innovative perspective for subcellular delivery and tumor treatment.
- 9 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (41)
Open AccessSenescent tumor cell membrane–based “time engine” nanosystem amplifies endoplasmic reticulum targeting for metastasis blockade
As an important component of biomimetic drug delivery systems, cell membrane–coated nanoparticles are widely used for subcellular delivery. However, the influence of cell membranes at different life cycles on subcellular delivery remains unexplored. Our previous study demonstrated that senescent tumor cell membrane–coated nanoparticles (SNP) displayed superior endoplasmic reticulum (ER) targeting efficiency in tumor cells. After inducing tumor cells into senescence, SNP showed greater accumulation in ER. Herein, we design a “time engine” nanosystem for amplified ER targeting: Firstly, ribociclib is encapsulated into SNP (R@SNP) to induce tumor cell senescence; then, SNP loaded with brefeldin A (B@SNP) is used to trigger ER stress. By sequential therapy, R@SNP disrupts the cytoskeleton of 4T1 tumor cells to eliminate ER-targeting barriers and remodels the tumor immune microenvironment; B@SNP boosts ER-targeting efficiency and triggers intense ER stress. Collectively, such time engine nanosystem achieves excellent ER accumulation and antimetastatic efficacy in 4T1 tumor–bearing mice, providing an innovative perspective for subcellular delivery and tumor treatment.
- Open Access
- 24 September 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
mtROS-bursting, acidity-neutralizing micelle boost and stabilize tumor NKG2D ligands for enhanced immunotherapy
- 24 September 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
Open AccessmtROS-bursting, acidity-neutralizing micelle boost and stabilize tumor NKG2D ligands for enhanced immunotherapy
- Open Access
- 24 September 2026
- Published by Springer Nature in Nature Communications
Spatiotemporal delivery of immune-synapse-stabilizing NK cells for postoperative tumor therapy
- 24 September 2026
- Published by Springer Nature in Nature Communications
Open AccessSpatiotemporal delivery of immune-synapse-stabilizing NK cells for postoperative tumor therapy
- Open Access
- 27 August 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1070
Advances in Living Cell-Mediated Nanodrug Delivery Systems: Construction Strategies, Applications and Challenges
Nanodrug delivery systems have shown great promise against tumors, inflammatory diseases and central nervous system disorders. However, several limitations still exist before further clinical application. The unsatisfactory circulation time in vivo, rapid clearance by the mononuclear phagocyte system, insufficient tissue penetration and low targeting efficiency all hinder the clinical translation of nanomedicines. Cells are the fundamental functional units of the body and their intrinsic biological properties make them promising drug delivery vehicles for targeted therapy. Conjugating cells with nanomedicines combines the carrier functions of living cells with the therapeutic effects of nanodrugs, offering an effective strategy to improve targeted drug delivery. Compared with the existing literature, this review specifically summarizes the biological properties and major applications of six types of living cell carriers. The recent strategies for constructing cell–nanomedicine conjugates are also discussed. Finally, we highlight the current challenges for clinical translation and discuss future directions for the development of cell–nanomedicine delivery systems.
- 27 August 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1070
Open AccessAdvances in Living Cell-Mediated Nanodrug Delivery Systems: Construction Strategies, Applications and Challenges
Nanodrug delivery systems have shown great promise against tumors, inflammatory diseases and central nervous system disorders. However, several limitations still exist before further clinical application. The unsatisfactory circulation time in vivo, rapid clearance by the mononuclear phagocyte system, insufficient tissue penetration and low targeting efficiency all hinder the clinical translation of nanomedicines. Cells are the fundamental functional units of the body and their intrinsic biological properties make them promising drug delivery vehicles for targeted therapy. Conjugating cells with nanomedicines combines the carrier functions of living cells with the therapeutic effects of nanodrugs, offering an effective strategy to improve targeted drug delivery. Compared with the existing literature, this review specifically summarizes the biological properties and major applications of six types of living cell carriers. The recent strategies for constructing cell–nanomedicine conjugates are also discussed. Finally, we highlight the current challenges for clinical translation and discuss future directions for the development of cell–nanomedicine delivery systems.
- Open Access
- 31 July 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (8) , 884
Recent Advances in Lipid Nanoparticle-Mediated Respiratory and Gastrointestinal Mucosal Delivery of Nucleic Acids
The clinical translation of nucleic acids is severely hindered by multiple delivery barriers, such as enzymatic degradation, poor cellular uptake, endosomal entrapment, and rapid systemic clearance. Despite the remarkable therapeutic potential of these agents, conventional delivery systems often fail to address these challenges. Lipid nanoparticles (LNPs) have emerged as a versatile platform to overcome these obstacles, offering tunable physicochemical properties, high encapsulation efficiency, and pH-responsive endosomal escape. This review summarizes recent advances in LNP-based respiratory and gastrointestinal mucosal delivery of nucleic acids, with emphasis on formulation strategies for overcoming mucus and epithelial barriers. To overcome mucosal barriers, LNP studies have shown that keeping particle size below the local mucus mesh size (~100 nm), tuning surface charge toward near-neutrality via pH-responsive ionizable lipids, and maintaining a neutral, deformable, moderately PEGylated surface during the mucin transport stage can increase transmucosal diffusivity several-fold over conventional cationic LNPs. We further discuss current limitations and propose future directions, emphasizing the need for the integration of the pathological and physiological characteristics of specific mucosa with artificial intelligence (AI) platforms to develop intelligent and personalized delivery platforms with “spatiotemporal adaptive” capabilities.
- 31 July 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (8) , 884
Open AccessRecent Advances in Lipid Nanoparticle-Mediated Respiratory and Gastrointestinal Mucosal Delivery of Nucleic Acids
The clinical translation of nucleic acids is severely hindered by multiple delivery barriers, such as enzymatic degradation, poor cellular uptake, endosomal entrapment, and rapid systemic clearance. Despite the remarkable therapeutic potential of these agents, conventional delivery systems often fail to address these challenges. Lipid nanoparticles (LNPs) have emerged as a versatile platform to overcome these obstacles, offering tunable physicochemical properties, high encapsulation efficiency, and pH-responsive endosomal escape. This review summarizes recent advances in LNP-based respiratory and gastrointestinal mucosal delivery of nucleic acids, with emphasis on formulation strategies for overcoming mucus and epithelial barriers. To overcome mucosal barriers, LNP studies have shown that keeping particle size below the local mucus mesh size (~100 nm), tuning surface charge toward near-neutrality via pH-responsive ionizable lipids, and maintaining a neutral, deformable, moderately PEGylated surface during the mucin transport stage can increase transmucosal diffusivity several-fold over conventional cationic LNPs. We further discuss current limitations and propose future directions, emphasizing the need for the integration of the pathological and physiological characteristics of specific mucosa with artificial intelligence (AI) platforms to develop intelligent and personalized delivery platforms with “spatiotemporal adaptive” capabilities.
- Open Access
- 22 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (21) , eaed3138
Erythrocyte patch for enhanced B cell depletion therapy
Dysregulated B cells are central to many hematologic malignancies and autoimmune diseases, but current B cell–targeted therapies often fail to translate binding into effective signaling. Here, we present CD20 EryPatch, a living dynamic cellular patch that co-opts natural erythrocyte processes of morphological and biological changes, enabling a dual mechanism of micrometer-scale mechanotransduction and phagocytic “tag-and-clear” for enhanced B cell depletion. CD20 EryPatches are designed to adhere to B cells and anchor on CD20 receptors across extensive cell surface areas. Their progressive discocyte-to-echinocyte transition provides deformability-driven traction, enabling localized, large-scale CD20 cross-linking that amplifies downstream apoptosis in target B cells. Concomitant biomarker alteration on CD20 EryPatch converts it into an “eat me” tag attached to the B cell, facilitating further clearance by initiating erythrophagocytosis. This approach proves more effective than standard CD20 monoclonal antibodies in models of B cell disorders, including non-Hodgkin lymphoma, systemic lupus erythematosus, and rheumatoid arthritis.
- 22 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (21) , eaed3138
Open AccessErythrocyte patch for enhanced B cell depletion therapy
Dysregulated B cells are central to many hematologic malignancies and autoimmune diseases, but current B cell–targeted therapies often fail to translate binding into effective signaling. Here, we present CD20 EryPatch, a living dynamic cellular patch that co-opts natural erythrocyte processes of morphological and biological changes, enabling a dual mechanism of micrometer-scale mechanotransduction and phagocytic “tag-and-clear” for enhanced B cell depletion. CD20 EryPatches are designed to adhere to B cells and anchor on CD20 receptors across extensive cell surface areas. Their progressive discocyte-to-echinocyte transition provides deformability-driven traction, enabling localized, large-scale CD20 cross-linking that amplifies downstream apoptosis in target B cells. Concomitant biomarker alteration on CD20 EryPatch converts it into an “eat me” tag attached to the B cell, facilitating further clearance by initiating erythrophagocytosis. This approach proves more effective than standard CD20 monoclonal antibodies in models of B cell disorders, including non-Hodgkin lymphoma, systemic lupus erythematosus, and rheumatoid arthritis.
- Open Access
- 10 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (15) , eaec7150
Targeting mitocytosis potentiates mitochondria drug delivery for antimetastasis therapy
Mitocytosis is a compensatory pathway responding to mitochondria stress in migratory cells, which expels damaged mitochondria through migrasomes, preserving mitochondrial homeostasis and cellular viability. We found distinct responses to mitochondria-targeted therapy across breast tumor models distinguished by migrasome expression (4T1 > E0771 > EMT6). The antimetastatic efficacy of mitochondrial damage was notably compromised in the migrasome-high 4T1 tumor model due to robust mitocytosis activation, which is merely explored and lacks effective strategy. Here, we developed a mitochondria-targeted nanoplatform (RH-NPs) with the functions of mitocytosis inhibition and mitochondrial damage. Mitochondria-targeted triphenylphosphonium-modified lonidamine (TPP-LND) and integrin inhibitor cilengitide (CGT) were separately loaded into a nanodelivery system (TL/RH-NPs and CGT/RH-NPs, respectively). TL/RH-NPs effectively targeted and damaged tumor mitochondria. Simultaneously, upon mitocytosis activation, CGT/RH-NPs hitchhiked with damaged mitochondria into migrasomes to block mitocytosis via integrin inhibition. This strategy significantly potentiated antimetastatic efficacy in 4T1 tumor models, which established an effective approach for mitocytosis modulation and optimization of mitochondria-targeted therapies.
- 10 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (15) , eaec7150
Open AccessTargeting mitocytosis potentiates mitochondria drug delivery for antimetastasis therapy
Mitocytosis is a compensatory pathway responding to mitochondria stress in migratory cells, which expels damaged mitochondria through migrasomes, preserving mitochondrial homeostasis and cellular viability. We found distinct responses to mitochondria-targeted therapy across breast tumor models distinguished by migrasome expression (4T1 > E0771 > EMT6). The antimetastatic efficacy of mitochondrial damage was notably compromised in the migrasome-high 4T1 tumor model due to robust mitocytosis activation, which is merely explored and lacks effective strategy. Here, we developed a mitochondria-targeted nanoplatform (RH-NPs) with the functions of mitocytosis inhibition and mitochondrial damage. Mitochondria-targeted triphenylphosphonium-modified lonidamine (TPP-LND) and integrin inhibitor cilengitide (CGT) were separately loaded into a nanodelivery system (TL/RH-NPs and CGT/RH-NPs, respectively). TL/RH-NPs effectively targeted and damaged tumor mitochondria. Simultaneously, upon mitocytosis activation, CGT/RH-NPs hitchhiked with damaged mitochondria into migrasomes to block mitocytosis via integrin inhibition. This strategy significantly potentiated antimetastatic efficacy in 4T1 tumor models, which established an effective approach for mitocytosis modulation and optimization of mitochondria-targeted therapies.
- Top Cited PapersOpen Access
- 17 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2497
Surface hydrophobicity and rigidity determines protein corona on orally delivered nanoparticles treating colitis
Disease-specific protein corona adsorbed on nanocarriers determines in vivo delivery efficiency. Macrophages can orchestrate inflammation resolution and mucosa repair, making them a promising therapeutic target in colitis. Here, we show that surface hydrophobicity and rigidity determine colitis-specific intestinal protein corona (C-IPC) on orally delivered nanoparticles for treating colitis, which improves therapeutic efficiency. We show that high surface hydrophobicity boosts overall protein adsorption, leading to improved colon macrophage delivery and therapeutic effect when loaded with budesonide. Moreover, hydrophobicity with high rigidity results in a corona enriched with macrophage-targeting proteins, notably S100A8, generating an optimal C-IPC characterized by both high protein amount and high proportion of targeting proteins. Consequently, high rigidity nanoparticles more effectively attenuates the inflammatory state and restores the immune homeostasis in male rats with colitis. Our work develops a rational strategy of manipulating protein corona formation through physicochemical properties for efficient oral drug delivery, holding broad promise for diverse nanocarriers and pathologies.
- 17 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2497
Top Cited PapersOpen AccessSurface hydrophobicity and rigidity determines protein corona on orally delivered nanoparticles treating colitis
Disease-specific protein corona adsorbed on nanocarriers determines in vivo delivery efficiency. Macrophages can orchestrate inflammation resolution and mucosa repair, making them a promising therapeutic target in colitis. Here, we show that surface hydrophobicity and rigidity determine colitis-specific intestinal protein corona (C-IPC) on orally delivered nanoparticles for treating colitis, which improves therapeutic efficiency. We show that high surface hydrophobicity boosts overall protein adsorption, leading to improved colon macrophage delivery and therapeutic effect when loaded with budesonide. Moreover, hydrophobicity with high rigidity results in a corona enriched with macrophage-targeting proteins, notably S100A8, generating an optimal C-IPC characterized by both high protein amount and high proportion of targeting proteins. Consequently, high rigidity nanoparticles more effectively attenuates the inflammatory state and restores the immune homeostasis in male rats with colitis. Our work develops a rational strategy of manipulating protein corona formation through physicochemical properties for efficient oral drug delivery, holding broad promise for diverse nanocarriers and pathologies.
- 3 March 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 393, 114773
Advances in non-invasive delivery strategies for anti-cancer therapy
- 3 March 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 393, 114773
Advances in non-invasive delivery strategies for anti-cancer therapy